Prescriber's Corner
Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
Bradley J. Yelvington, PharmD
Vanderbilt University Medical Center—Pharmacy, Nashville, Tennessee
Author’s disclosures of conflicts of interest are found at the end of this article.
Bradley J. Yelvington, PharmD, 1301 Medical Center Drive, Room 3910, The Vanderbilt Clinic, Nashville, Tennessee 37232.
E-mail: bradley.j.yelvington@vanderbilt.edu
J Adv Pract Oncol 2018;9(5):530–534 |
https://doi.org/10.6004/jadpro.2018.9.5.7 |
© 2018 Harborside™
ABSTRACT
Abstract
Rituximab and hyaluronidase human is a new subcutaneous formulation of rituximab that was recently approved by the US Food and Drug Administration for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. With data to support noninferior pharmacokinetics, similar outcomes, and comparable adverse events, rituximab and hyaluronidase human may offer a suitable alternative to intravenous rituximab that could improve convenience for patients and better utilize health-care resources.
For access to the full length article, please
sign in.
